Cytogenetic studies of an adrenal cortical carcinoma

Marks, James L.; Wyandt, Herman E.; Beazley, Robert M.; Milunsky, Jeffrey M.; Sheahan, Kieran; Milunsky, Aubrey

doi:10.1016/0165-4608(92)90377-k

Cited by 9 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Karyotyping studies of ACCs demonstrated that ACCs present a large number of chromosomal aberrations, including segmental duplications, rearrangements and aberrant chromosomes. Cytogenetic and flow cytometry studies further corroborated these findings, demonstrating that most ACCs exhibit aneuploidy/polyploidy, while ACAs are almost always diploid (Klein, Kay et al 1985, Bowlby, DeBault et al 1986, Limon, Dal Cin et al 1987, Marks, Wyandt et al 1992). Clonality studies have shown that, while ACCs are invariably of monoclonal origin, some ACAs can be polyclonal (Beuschlein, Reincke et al 1994, Gicquel, Leblond-Francillard et al 1994).…”

Section: Genetic Aspects Of Adrenocortical Carcinoma (Acc)mentioning

confidence: 61%

Genetics and epigenetics of adrenocortical tumors

Lerário¹,

Moraitis²,

Hammer³

2014

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Adrenocortical tumors are common neoplasms. Most are benign, nonfunctional and clinically irrelevant. However, adrenocortical carcinoma is a rare disease with a dismal prognosis and no effective treatment apart from surgical resection. The molecular genetics of adrenocortical tumors remain poorly understood. For decades, molecular studies relied on a small number of samples and were directed to candidate-genes. This approach, based on the elucidation of the genetics of rare genetic syndromes in which adrenocortical tumors are a manifestation, has led to the discovery of major dysfunctional molecular pathways in adrenocortical tumors, such as the IGF pathway, the Wnt pathway and TP53. However, with the advent of high-throughput methodologies and the organization of international consortiums to obtain a larger number of samples and high-quality clinical data, this paradigm is rapidly changing. In the last decade, genome-wide expression profile studies, microRNA profiling and methylation profiling allowed the identification of subgroups of tumors with distinct genetic markers, molecular pathways activation patterns and clinical behavior. As a consequence, molecular classification of tumors has proven to be superior to traditional histological and clinical methods in prognosis prediction. In addition, this knowledge has also allowed the proposal of molecular-targeted approaches aiming better treatment options for advanced disease. This review aims to summarize the most relevant data on the rapidly evolving field of genetics of adrenal disorders.

show abstract